362 related articles for article (PubMed ID: 33107145)
1. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
[TBL] [Abstract][Full Text] [Related]
2. Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models.
Beheshti A; Stevenson K; Vanderburg C; Ravi D; McDonald JT; Christie AL; Shigemori K; Jester H; Weinstock DM; Evens AM
Sci Rep; 2019 Nov; 9(1):17161. PubMed ID: 31748664
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.
Sun R; Zhang PP; Weng XQ; Gao XD; Huang CX; Wang L; Hu XX; Xu PP; Cheng L; Jiang L; Fu D; Qu B; Zhao Y; Feng Y; Dou HJ; Zheng Z; Zhao WL
Signal Transduct Target Ther; 2022 Mar; 7(1):80. PubMed ID: 35301282
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs.
Paszkiewicz-Kozik E; Paziewska A; Kulecka M; Dąbrowska M; Kluska A; Bałabas A; Piątkowska M; Ambrożkiewicz F; Tajer J; Osiadacz W; Romejko-Jarosińska J; Kotarska M; Żeber-Lubecka N; Karczmarski J; Popławska L; Mikula M; Rutkowski P; Walewski J; Ostrowski J
Biomed Res Int; 2021; 2021():3212878. PubMed ID: 33628777
[TBL] [Abstract][Full Text] [Related]
7. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.
Azzaoui I; Uhel F; Rossille D; Pangault C; Dulong J; Le Priol J; Lamy T; Houot R; Le Gouill S; Cartron G; Godmer P; Bouabdallah K; Milpied N; Damaj G; Tarte K; Fest T; Roussel M
Blood; 2016 Aug; 128(8):1081-92. PubMed ID: 27338100
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic Value of CD14
Wu CX; Qiang M; Hao JQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):816-819. PubMed ID: 31204937
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
[TBL] [Abstract][Full Text] [Related]
11. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
13. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
14. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
15. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
16. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
17. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
Regazzo G; Marchesi F; Spagnuolo M; Díaz Méndez AB; Masi S; Mengarelli A; Rizzo MG
Blood Rev; 2021 May; 47():100776. PubMed ID: 33229139
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]